Hematology Advisor

Placental Growth Factor Shows Utility for Predicting Early-Onset Preeclampsia SCD Researchers determined evaluation of levels of PlGF showed utility in prediction of early-onset preeclampsia in pregnant individuals with SCD.

Evaluation of levels of placental growth factor showed utility in prediction of early-onset preeclampsia in pregnant individuals with #sickleCellDisease. Reported in @bloodjournals.hematology.org.

https://bit.ly/4puSInj

#SCD

#Daratumumab is safe and effective in allowing patients with #iTTP to achieve ADAMTS13 remission. Presented at #ASH25.

https://bit.ly/48HbIb9

KRd significantly prolonged PFS and improved the MRD negativity rate compared to VRd in newly diagnosed #multipleMyeloma. Presented at #ASH25, covered by @cancertherapyadv.bsky.social.

Read more here: ➡️ https://bit.ly/48NmWe6

#NDMM

Patients with primary #ITP who received treatment with efgartigimod experienced sustained improvements in #HRQoL measures. Presented at #ASH25.

https://bit.ly/3XGSRYT

The Rise of Medical Influencers Medical influencers and social media, having changed the ways in which physicians communicate, now carry certain ethical responsibilities.

Medical professionals who use #socialmedia to educate the public on health-related topics have grown in prominence. From @renalurologynews.bsky.social.

https://bit.ly/4pSQnmh

#MedicalInfluencer

Sonrotoclax Gets Priority Review for R/R Mantle Cell Lymphoma A next-generation BCL2 inhibitor, sonrotoclax, receives FDA Priority Review for previously treated relapsed or refractory mantle cell lymphoma.

The @fda.gov has granted Priority Review to the NDA for sonrotoclax for the treatment for patients with R/R #mantleCellLymphoma, following treatment with a BTK inhibitor. From @medicalprofref.bsky.social.

https://bit.ly/3XxY9pq

#lymsm

Immune-Modulating Therapy Achieves Successful Pregnancies in CIUE With FNAIT-Like Injury Chronic histiocytic intervillositis of unknown etiology in the context of FNAIT-like fetal-specific anti-HLA responses responded to a transplant-derived immunosuppressive regimen.

Reversal of recurrent pregnancy loss associated with CIUE was achieved through an immunosuppressive protocol directed at antibody-mediated alloimmunity, a mechanism closely related to that seen in #FNAIT. From @frontiersin.bsky.social and @rarediseaseadvisor.bsky.social.

https://bit.ly/4ixvbzs

Significant Barriers Exist in Accessing Initial Oncology Care Among Young Adults with ALL Researchers determined AYAs with ALL trying to schedule oncology appointments face logistical burdens when accessing initial oncology care.

A secret shopper study in which researchers posed as AYAs with acute #lymphoblasticLeukemia trying to schedule an #oncology appointment has found that this population faces significant logistical burdens when accessing initial oncology care.

https://bit.ly/3XBFHfA

#leusm #ASCO25

Study Will Assess Role of MRI in Detecting Abnormalities in Hemophilic Knee Joints The study will evaluate concordance between the IPSG and x-ray scoring systems in detecting joint changes in hemophilic arthropathy.

A new study will evaluate the role of #MRI in identifying synovial, cartilaginous, and osseous, and intra-articular bleeding abnormalities in the knees of patients with #hemophilia A or B. From @rarediseaseadvisor.bsky.social.

https://bit.ly/441nKLa

Apixaban Safe, Effective as VTE Prophylaxis in Obese Pediatric Patients With ALL/LL Researchers determined apixaban is safe and effective as VTE prophylaxis in obese pediatric patients with ALL/LL.

Apixaban is safe and effective as VTE prophylaxis in #obese pediatric patients with acute #lymphoblasticLeukemia and lymphoma. Published in @bloodjournal.bsky.social.

https://bit.ly/4ap9bow

#leusm

Azacitidine May Be Effective in VEXAS Syndrome In a retrospective study, azacitidine resulted in hematologic and inflammatory responses in the majority of patients with VEXAS syndrome.

Azacitidine treatment of #VEXASsyndrome resulted in improved hematologic and inflammatory responses in the majority of patients in a retrospective study. Published in @bloodjournals.hematology.org.

https://bit.ly/3XvJDP6

#HemOnc

Thrombate III Approved for Hereditary Antithrombin Deficiency in Children The FDA has expanded the approval of Thrombate III to include pediatric patients with hATd to treat and prevent thromboembolism.

The @fda.gov has expanded the approval of Thrombate III® to include the treatment of pediatric patients with hereditary #antithrombinDeficiency, in addition to adults. From @medicalprofref.bsky.social.

https://bit.ly/3LQihAD

#PediatricHematology

County-Level Smoking Prevalence Tied to Multiple Primary Cancer Risk In this study, researchers examined associations between multiple primary cancer incidence and county-level smoking prevalence. High prevalence of smoking at the county level is linked to a higher-than-expected incidence of multiple primary cancers, res...

High prevalence of #smoking at the county level is linked to a higher-than-expected incidence of multiple primary #cancers. Published in @theaacr.bsky.social journal Cancer Epidemiology, Biomarkers & Prevention, and @cancertherapyadv.bsky.social.

https://bit.ly/4rqkSS7

FDA Grants Traditional Approval to Darzalex Faspro for AL Amyloidosis The FDA has granted traditional approval to Darzalex Faspro in combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adults with newly diagnosed light chain amyloidosis.

The @fda.gov has granted traditional approval to Darzalex Faspro® in combination with VCd for the treatment of adults with newly diagnosed #ALAmyloidosis. From @medicalprofref.bsky.social.

https://bit.ly/44hz4Tm

Repeated Surveys Strengthen Preventive Care Engagement in CLL Serial participation was associated with improved cumulative vaccine coverage.

Vaccination and #cancerScreening uptake improved over time among patients with #CLL who repeatedly completed annual health maintenance questionnaires. Presented at upcoming #ASH25. From @rarediseaseadvisor.bsky.social.

https://bit.ly/4oToytP

#leusm

CAR-T Availability Necessary for Combatting Health Disparities in MM Patients with MM who are part of racial and ethnic minority populations have reduced access to BCMA-targeting CAR-T therapies.

Among racial and ethnic minority populations, patients with #multipleMyeloma have reduced access to BCMA-targeting CAR T-cell therapies.

https://bit.ly/43N6zgf

#HealthDisparities

Mixed Results for Mitapivat in Sickle Cell Disease Trial Topline results from the RISE UP phase 3 trial demonstrated that mitapivat significantly improved hemoglobin response in patients with sickle cell disease.

Topline results were announced from a phase 3 trial evaluating #mitapivat, an oral pyruvate kinase activator, in patients with #sickleCellDisease.

https://bit.ly/4pABm8v

Quizartinib Improves Survival in Newly Diagnosed FLT3-ITD–Negative AML Researchers determined quizartinib plus chemotherapy significantly improved event-free survival and overall survival in patients with newly diagnosed FLT-ITD–negative AML.

Adding the FLT3 inhibitor quizartinib to standard chemotherapy significantly improved EFS and OS in patients with newly diagnosed FLT-ITD–negative #acuteMyeloidLeukemia. Published in @ascopost.bsky.social.

https://bit.ly/48hcziF

#AML #leusm

What Is Aplastic Anemia? Symptoms, Causes, and Procedure Aplastic anemia is a rare blood disease where the bone marrow stops making enough new blood cells, with symptoms like pale skin and fatigue.

#AplasticAnemia is a rare blood disease that occurs when the bone marrow stops making enough new blood cells.

https://bit.ly/4ijicl2

#anemia

Hybrid Immunity Significantly Reduces Long COVID Risk in Health Care Workers COVID-19 vaccination, especially with prior infection, significantly reduced the risk for long COVID in health care workers.

#COVID19vaccination, particularly when combined with prior infection, substantially reduces the risk for #longCOVID among #HCWs. Published in @cidjournal.bsky.social and @infectiousdisease.bsky.social.

https://bit.ly/43HuFc5

#COVID19

Granulomatous Acute Interstitial Nephritis Can Cause Renal Dysfunction in CLL The patient initiated treatment with zanubrutinib and high-dose corticosteroids, resulting in partial improvement in renal function.

Granulomatous acute interstitial nephritis is a rare but important cause of renal dysfunction in patients with chronic #lymphocyticLeukemia. From @rarediseaseadvisor.bsky.social.

https://bit.ly/49u4fym

#CLL #leusm

Distinct Care Strategies Are Needed for Mild Hemophilia Predicting bleeding risk and concerns regarding over- or undertreating were common concerns among clinicians.

#Hematologists in the United States report significant disparities in diagnostic and treatment approaches for individuals with mild #hemophilia. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/48oCp5m

Ruxolitinib Superior to Best Available Therapy in Managing Steroid-Refractory Acute GVHD Researchers determined ruxolitinib performed better than best available therapy in the management of a cohort of patients with SR-aGVHD over a 24-month period.

Ruxolitinib performed better than best available therapy in the management of a cohort of patients with SR-aGVHD over a 24-month period. Published in the @ascopost.bsky.social journal Journal of Clinical Oncology.

https://bit.ly/3XEBLuq

#GVHD

Diagnostic Delays Associated With Increased Mortality in VTE Researchers determined diagnostic delays for patients having symptoms of VTE were associated with increased rates of all-cause mortality.

Diagnostic delays for patients having symptoms of #VTE were associated with increased rates of all-cause mortality. Reported in @jamanetworkopen.com.

https://bit.ly/44cOqZf

Significant Barriers Exist in Accessing Initial Oncology Care Among Young Adults with ALL Researchers determined AYAs with ALL trying to schedule oncology appointments face logistical burdens when accessing initial oncology care.

A secret shopper study in which researchers posed as AYAs with acute #lymphoblasticLeukemia trying to schedule an #oncology appointment has found that this population faces significant logistical burdens when accessing initial oncology care. From #ASCO25.

https://bit.ly/4ib5gh0

#leusm #lymsm

Anxiety Increases irAEs but Boosts OS in Cancer Patients Receiving Immunotherapy Study researchers noted that the findings suggest the association between anxiety and improved OS was at least partly related to the higher incidence of irAEs, which implies that, in people with an anxiety disorder, immunotherapy “may result in greater ...

When treated with ICIs, #cancerpatients with a pre-existing anxiety diagnosis appear to experience more irAEs and have better OS than those without anxiety. Published in @cancertherapyadv.bsky.social.

https://bit.ly/4894cqo

Predicting Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia Researchers developed a model to aid in individualized decision making around the use of prophylactic platelet transfusion in preterm infants who have severe thrombocytopenia.

Researchers developed a new model to aid in individualized decision making around the use of prophylactic platelet transfusion in preterm infants who have severe #thrombocytopenia. Reported in @jama.com.

https://bit.ly/47KN1LX

Addressing Racial and Ethnic Disparities in VTE, DVT Treatment and Outcomes Studies have indicated there are racial and ethnic disparities in the treatment and outcomes of patients with VTE or DVT.

Multiple studies have demonstrated variable incidence rates of #VTE across racial and ethnic groups in the United States.

https://bit.ly/43LvCjR

#HealthDisparities

Mosunetuzumab Plus Polatuzumab Vedotin Yields High CR Rate in Relapsed, Refractory LBCL Researchers determined combining mosunetuzumab with polatuzumab vedotin appears to reduce the risk of disease progression or death compared with R-GemOx in LBCL.

Among patients with transplant-ineligible R/R #LBCL, combining mosunetuzumab with polatuzumab vedotin appears to reduce the risk of disease progression or death compared with R-GemOx. Published in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/3WQSyKr

#lymphoma #lymsm

Use of Alternative Donor HCT Limited in Patients With Severe Aplastic Anemia In patients with SAA, upfront allogeneic HCT using alternative donors has become an option for some, but this method has had limited utilization.

In patients with severe #aplasticAnemia, upfront allogeneic HCT using alternative donors has become an option for some, but this method has had limited utilization. From @bloodjournals.hematology.org.

https://bit.ly/48bV1FK

#anemia